Table 4. Literature review of intramucous, moderately differentiated, endometrioid endometrial cancers conservatively treated.
| Author (yr), [Reference] | Study design | No. of cases | BMI (kg/m2) | Treatment | Oncologic outcomes | Time to CR (mo) | Relapse | DFI (mo) | Pregnancy (No. of patients) | Live births | Follow-up (mo) | Current status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Brown et al. (2012), [3] | R | 1 | 47.7 | LNG-IUD (20 µg/d) | CR | 3 | 0 | n/a | 0 | 0 | 13 | NED |
| Falcone et al. (2017), [4] | P | 1 | 24.3 | HR + LNG-IUD (20 µg/d) | Prog | n/a | n/a | n/a | n/a | n/a | 78 | NED |
| Gotlieb et al. (2003), [5] | R | 2 | n/r | MPA (200–600 mg/d) | CR | 3–5 | 1 | 40 | 1 | 3 | 18–94 | NED |
| Han et al. (2009), [6] | R | 2 | n/r | MA (80 mg/d) or MPA (500 mg/d) | CR | 3 | 0 | n/a | 2 | 0 | 42–52 | NED |
| Hwang et al. (2017), [7] | R | 5 | 18.5–30.5 | MPA (500 mg/d) + LNG-IUD (20 µg/d) | 3 CR; 2 PR | 6–18 | 1 | 14 | 1 | 0 | 12–71 | NED |
| Imai et al. (2001), [8] | R | 2 | n/r | MPA (600 mg/d) | 1 CR; 1 PD | 9 | 1 | 7 | 0 | 0 | 7–47 | 1 NED; 1 LTFU |
| Kaku et al. (2001), [9] | R | 2 | <27.3 | MPA (600–800 mg/d) | 1 CR; 1 PD | 4 | 0 | n/a | 1 | 1 | 19–22 | NED |
| Kim et al. (2016), [10] | R | 1 | 24.8 | MA (160 mg/d) | CR | 8 | 0 | n/a | 0 | 0 | 8 | NED |
| Koskas et al. (2011), [11] | R | 3 | n/r | MA (160 mg/d), NG (5 mg/d) or NET (20 mg/d) | CR | 3–6 | 2 | 3–36 | 1 | 2 | 6–60 | 1 AWD; 2 NED |
| Le Digabel et al. (2006), [12] | R | 1 | n/r | Repetitive D&C | CR | n/r | 0 | n/a | 0 | 0 | 39 | NED |
| Leone Roberti Maggiore et al. (2019), [13] | R | 4 | 16.8–45.8 | LNG-IUD (20 µg/d) | 3 CR; 1 Prog | 4 | 3 | 12–16 | 0 | 0 | 112–118 | NED |
| Pal et al. (2018), [14] | R | 8 | 20–74 | LNG-IUD (20 µg/d) | 3 CR; 2 PD; 3 PR | 3–9 | n/r | n/r | n/r | n/r | n/r | n/r |
| Park et al. (2013), [15] | R, M | 14 | 18.5–38.2 | MA (40–240 mg/d) or MPA (80–1,000 mg/d) | 11 CR; 3 PD | 3–12 | 3 | 8–20 | 3 | n/r | 7–136 | NED |
| Rossetti et al. (2014), [16] | R | 2 | 20–23 | MA (160 mg/d) | CR | 6 | 2 | 13–18 | 2 | 2 | 14–52 | NED |
| Zuckerman et al. (1998), [17] | R | 1 | n/r | MPA (600 mg/d) | CR | 3 | 0 | n/a | 1 | 2 | n/r | NED |
| Total | - | 49 | - | - | 35 CR; 7 PD; 5 PR; 2 Prog | 3–18 | 13 | 3–40 | 12 | 10 | 6–136 | 39 NED; 1 AWD; 9 LTFU / n/r |
AWD, alive with disease; BMI, body mass index; CR, complete regression; D&C, dilation and curettage; DFI, disease-free interval; HR, hysteroscopic resection; LNG-IUD, levonorgestrel intrauterine device; LTFU, lost to follow-up; M, multicentric; MA, megestrol acetate; MPA, medroxyprogesterone acetate; n/a, not applicable; NED, no evidence of disease; NET, norethisterone; NG, nomegestrol; n/r, not reported; P, prospective; PD, persistent disease; PR, partial regression; Prog, progression; R, retrospective.